Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8264)	5/5/2003 11:26:24 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 52153

What caught my eye--beyond the simple humanity of the approval--is the fact that McCLellan put himself out in front of it publicly. He's been making the right comments in interviews about not hindering the progress of useful drugs, so if this is his way of heralding his willingness to push that agenda inhouse, that would be very good news indeed. Accelerated approvals with an emphasis upon Phase IV evaluation of clinical utility....that's just almost too reasonable to be true. Hope someone has told Russell Katz (CNS Division) that there's a new sheriff in town. Harry Tracy NeuroInvestment

To: Biomaven who wrote (8264)	5/6/2003 12:02:45 AM
From: Miljenko Zuanic	Respond to of 52153

<<They couldn't even find a subgroup where it worked well. This is one negative result that deserves a thorough article analyzing it.>> Maybe they did? Sunday 1:00 PM - 5:00 PM 2523 - Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non-small-cell lung cancer (NSCLC). Authors: R. S. Herbst, G. Giaccone, J. Schiller, V. Miller, R. Natale, P. Rennie, J. Ochs, A. Fandi, J. Grous, D. Johnson; University of Texas MD Anderson Cancer Center, Houston, TX; Free University Hospital, Amsterdam, Netherlands; University of Wisconsin Hospital and Clinics, Madison, WI; Memorial Sloan-Kettering Cancer Center, New York, NY; Cedars-Sinai Comprehensive Cancer Center, Beverly Hills, CA; AstraZeneca, Macclesfield, UK; AstraZeneca, Wilmington, DE; Vanderbilt-Ingram Cancer Center, Nashville, TN Presenter: Roy S. Herbst Chair(s): Alex A. Adjei; Mark A. Socinski Keyword(s): Gefitinib, Epidermal growth factor receptor tyrosine inhibitors, ZD1839 Category: Non-Small-Cell Lung Cancer Lung Cancer Poster Discussion S106 <<I guess attention will now shift to Tarceva.>> More broad. What is makeup of the various TK growth factor that determine response to certain drugs, as well that control aggressiveness of the cancer? Miljenko